Stock Analiz

Grace Therapeutics, Inc. GRCE

Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026

$1.81Market cap $38M
Open the interactive analysis →

Grace Therapeutics, Inc. (GRCE) is a healthcare company listed in the US with a market value of about $38M.

Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is financial health (4/5); the weakest is future growth (0/5).

Key numbers: a 5-year average ROIC of -25%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 365% above the current price.

About Grace Therapeutics

Grace Therapeutics is listed in the US and classified in biotechnology: pharmaceutical preparations. It was profitable in 0 of the last 10 years in our data.

Score: 1.0 / 5

Value1/5
Future growth0/5
Track record0/5
Financial health4/5
Shareholder returns0/5

Checks passed

  • Price below intrinsic value (DCF, moderate assumptions)
  • More cash than debt, or low debt to equity
  • Interest covered more than 5 times
  • Debt below 3 years of free cash flow
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving
  • 3-year free cash flow growth above 10% a year

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S—
P/B0.7
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield—
Shareholder yield0.0%
Intrinsic value vs. price+365%

Growth and quality

Revenue growth (1 yr)—
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-9.8%
ROIC (5-yr avg.)-25.4%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 10 years

Fiscal year2026202520242023202220212020201920182017
Revenue————$100M$196000————
Net income-$8M-$10M-$13M-$42M-$10M-$20M-$26M-$39M-$17M-$8M
Free cash flow———-$16M-$17M-$14M-$23M-$25M-$10M-$7M
EPS (diluted)$-0.37$-0.45$-0.61$-2.02$-0.47$-0.94$-1.21$-1.87$-0.79$-0.38
Net margin————-9.8%-10039.8%————
ROIC-14.2%-18.8%-18.2%-62.2%-13.5%-29.4%-186.0%-311.5%-167.7%-37.0%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 2 analysts is $5.84, 223% above the current price; targets range from $3.88 to $7.80; the consensus rating is “Strong buy”; expected EPS is $-0.76 for the fiscal year ending March 31, 2027.

Frequently asked questions

Is Grace Therapeutics stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 365% above the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Grace Therapeutics pay a dividend?

Not currently.

Is Grace Therapeutics a good stock to buy?

We do not give buy or sell advice. Grace Therapeutics scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.